Angiogenesis as a therapeutic target
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As compared to the traditional transwell method, the monolayer design also has the added advantage of easily generating shear stress.”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“This monolayer approach is very effective in applications where cylindrical vessel geometry of blood vessels is not very essential to the study, such as in the testing of drugs which prevent cancer cell migration because this method is high throughput and simple to fabricate [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“Shear stress helps cells arrange themselves to establish the barrier function [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“This followed from a phase III study showing a survival benefi”
BackgroundSelf-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundSelf-citationIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“reported the isolation of putative EPC from human peripheral blood, on the basis of cell-surface expression of CD34 and other endothelial marker”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“An alternative hypothesis has been proposed by Jai”
BackgroundTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“Several fragments of larger proteins have been described as endogenous inhibitors of angiogenesis including endostati”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citation
Research works printed but not linked: 1
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
Cited by
Items 901–1,000 of 1,007
Temming, K., Meyer, D. L., Zabinski, R. F., Senter, P. D., Poelstra, K., Molema, G., & Kok, R. J. (2007) · Molecular Pharmaceutics · doi:10.1021/mp0700312 · Cited by 45
The effect of lipoic acid on wound healing in a full thickness uterine injury model in rats
Mıçılı, S. Ç., Göker, A., Sayın, O., Akokay, P., & Ergür, B. U. (2013) · Journal of Molecular Histology · doi:10.1007/s10735-013-9485-8 · Cited by 46
Tsuchida, R., Osawa, T., Wang, F., Nishii, R., Das, B., Tsuchida, S., Muramatsu, M., Takahashi, T., Inoue, T., Wada, Y., et al. (2013) · Oncogene · doi:10.1038/onc.2013.358 · Cited by 44
Antiangiogenic properties of cafestol, a coffee diterpene, in human umbilical vein endothelial cells
Wang, S., Yoon, Y. C., Sung, M., Hur, H. J., & Park, J. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.04.046 · Cited by 53
Herzlich, A. A., Ding, X., Shen, D., Ross, R. J., Tuo, J., & Chan, C. (2009) · The Open Biology Journal · doi:10.2174/1874196700902010141 · Cited by 49
“The findings of increased expression of PPAR and its downstream proteins (VEGF, MMP9, and HO-1) in H2O2-treated ARPE19 cells, Ccl2 -/- /Cx3cr1 -/- mice, and human AMD eyes, but decreased VEGF in fat-1 mice, suggest that PPAR may play a role in AMD.”
BackgroundSmet, F. D., Tembuyser, B., Lenard, A., Claes, F., Zhang, J., Michielsen, C., Schepdael, A. V., Herbert, J., Bono, F., Affolter, M., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.07.018 · Cited by 46
Huang, C., Chuang, C., Lo, T.-F., & Hu, M. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.01.003 · Cited by 45
“Angiogenesis is tightly controlled by a wide variety of regulators which include cytokines [8-14] and matrix metalloproteinases (MMPs) [15,16] by tumors or the immune system.”
BackgroundMatkar, P. N., Singh, K. K., Rudenko, D., Kim, Y. J., Kuliszewski, M. A., Prud’homme, G. J., Hedley, D. W., & Leong-Poi, H. M. (2016) · Oncotarget · doi:10.18632/oncotarget.11060 · Cited by 48
Recent Advances in Peptide-Based Approaches for Cancer Treatment
Conibear, A. C., Schmid, A., Kamalov, M., Becker, C. F. W., & Bello, C. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867325666171123204851 · Cited by 45
Yang, Y., Tang, J., Zhang, M., Gu, Z., Song, H., Yang, Y., & Yu, C. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b02691 · Cited by 44
Yao, J., Gao, W., Wang, Y., Wang, L., Diabakte, K., Li, J., Yang, J., Jiang, Y., Liu, Y., Guo, S., et al. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.007 · Cited by 46
Zhong, C., Li, P., Argade, S. P., Liu, L., Chillà, A., Liang, W. P., Xin, H., Eliceiri, B. P., Choudhury, B., & Ferrara, N. (2020) · Nature Communications · doi:10.1038/s41467-020-20108-0 · Cited by 47
Self-citationHou, J., He, Z., Liu, T., Chen, D., Wang, B., Wen, Q., & Zheng, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.755053 · Cited by 58
“In addition, some other cytokines and growth factors could be potential targets in antiangiogenic therapy (106, 107).”
BackgroundDai, M., Yang, Y., Omelchenko, I., Nuttall, A. L., Kachelmeier, A., Xiu, R., & Shi, X. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100340 · Cited by 49
Bevacizumab in Non-Small Cell Lung Cancer
Costanzo, F. D., Mazzoni, F., Mela, M. M., Antonuzzo, L., Checcacci, D., Saggese, M., & Costanzo, F. D. (2008) · Drugs · doi:10.2165/00003495-200868060-00002 · Cited by 44
Wright, J. D., Secord, A. A., Numnum, T. M., Rocconi, R. P., Powell, M. A., Berchuck, A., Alvarez, R. D., Gibb, R. K., Trinkaus, K. M., Rader, J. S., et al. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01027.x · Cited by 44
Peroxisome proliferator-activated receptor and age-related macular degeneration
Herzlich, A. A., Tuo, J., & Chan, C.-C. (2008) · PPAR Research · doi:10.1155/2008/389507 · Cited by 43
“VEGF was first identified in the early 1970s as a tumorangiogenesis factor that is mitogenic to capillary endothelial cells in human tumors [95].”
Gambogic acid inhibits angiogenesis through inhibiting PHD2–VHL–HIF-1α pathway
Lu, N., Hui, H., Yang, H., Zhao, K., Chen, Y., You, Q., & Guo, Q. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.02.018 · Cited by 44
“Angiogenesi s plays an important role in tumor growth and has been a promising strategy for treatment of cancer (Ferrara and Kerbel, 2005 ).”
BackgroundAra, M. N., Hyodo, M., Ohga, N., Hida, K., & Harashima, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050174 · Cited by 44
Pander, J., Wessels, J. A. M., Gelderblom, H. A. J., van der Straaten, T., Punt, C. J. A., & Guchelaar, H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq572 · Cited by 50
“Bevacizumab neutralizes VEGF, resulting in decreased tumor angiogenesis, which in turn affects intratumoral hypoxia, nutrition status and/or disposition of concurrent chemotherapy [54].”
Saruwatari, K., Ikemura, S., Sekihara, K., Kuwata, T., Fujii, S., Umemura, S., Kirita, K., Matsumoto, S., Yoh, K., Niho, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.11.012 · Cited by 45
Pi, J., Tao, T., Zhuang, T., Sun, H., Chen, X., Liu, J., Cheng, Y., Yu, Z., Zhu, H. H., Gao, W., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.309757 · Cited by 43
Wang, W., Liu, Y., You, L., Sun, M., Qu, C., Dong, X., Yin, X., & Ni, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110750 · Cited by 43
Xing, Z., Zhao, C. F., Wu, S., Zhang, C., Liu, H., & Fan, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120872 · Cited by 45
Jung, K., Lee, D. H., Lim, H. S., Lee, S., Kim, Y. J., Lee, G. M., Kim, S. C., & Koh, G. Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228130 · Cited by 43
Ding, W. J., Hill, J. J., & Kelly, J. F. (2007) · Analytical Chemistry · doi:10.1021/ac0707535 · Cited by 43
Alférez, D., Wilkinson, R. W., Watkins, J., Poulsom, R., Mandir, N., Wedge, S. R., Pyrah, I. T. G., Smith, N. R., Jackson, L., Ryan, A. J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0433 · Cited by 47
“Tumor growth is highly dependent on angiogenesis to ensure an adequate supply of oxygen and nutrients (10), and vascular endothelial growth factor (VEGF)-A is considered to be a critical factor in promoting the angiogenic cascade through binding to VEGF receptor (VEGFR) 2 (11).”
BackgroundJugold, M., Palmowski, M., Huppert, J., Woenne, E. C., Mueller, M. M., Semmler, W., & Kiessling, F. M. (2007) · European Radiology · doi:10.1007/s00330-007-0825-5 · Cited by 43
“The collapse of vascularization withdraws basic requirements for nutrition of the tumor and as a consequence leads to tumor regression and necrotic degeneration [2, 3].”
BackgroundCanavese, M., Ngo, D. T. M., Maddern, G. J., Hardingham, J. E., Price, T. J., & Hauben, E. (2016) · International Journal of Cancer · doi:10.1002/ijc.30567 · Cited by 46
“This mechanism of action should allow the blockage of tumor progression at different levels, acting on malignant cells, macrophages and stromal cells that contribute with cooperative mechanisms to tumor neovascularization.(23,24) Given the different mechanisms of action of aflibercept and ramucirumab in secondline the…”
BackgroundAdelfinger, M., Bessler, S., Frentzen, A., Cecil, A., Langbein-Laugwitz, J., Gentschev, I., & Szalay, A. A. (2015) · Viruses · doi:10.3390/v7072811 · Cited by 46
“VEGF or its pathway have been successfully targeted with antibodies and small molecules [14,15].”
BackgroundATP-Sensitive Potassium Channel Activation Induces Angiogenesis In Vitro and In Vivo
Umaru, B., Pyriochou, A., Kotsikoris, V., Papapetropoulos, A., & Topouzis, S. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222000 · Cited by 47
“…such as in alleviating the sequelae of ischemic heart disease and peripheral artery disease or when curbing ectopic or excessive angiogenic growth is desirable, as in solid tumor growth and in diabetic retinopathy (Coultas et al., 2005; Ferrara and Kerbel, 2005; Carmeliet and Jain, 2011).”
BackgroundInfluentialTargeting angiogenesis in advanced cervical cancer
Eskander, R. N., & Tewari, K. S. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014543794 · Cited by 44
“2004; Ferrara, 2005; Ferrara and Kerbel, 2005].”
Thapa, D., Lee, J. S., Heo, S., Lee, Y. R., Kang, K. W., Kwak, M., Choi, H. G., & Kim, J. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.073 · Cited by 43
Tumor cell response to bevacizumab single agent therapy in vitro
Hein, M., & Graver, S. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-94 · Cited by 42
“Signaling through its receptors VEGFR1 (FLT-1), VEGFR2 (FLK-1) and co-receptor Neuropilin1 (NRP1) on endothelia represents the best characterized pathway in angiogenesis [4].”
BackgroundHassan, B. B., Elshafae, S. M., Supsavhad, W., Simmons, J. K., Dirksen, W. P., Sokkar, S. M., & Rosol, T. J. (2016) · Veterinary Pathology · doi:10.1177/0300985816650243 · Cited by 54
Morbidelli, L. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.011 · Cited by 43
MiR-145 functions as a tumor suppressor via regulating angiopoietin-2 in pancreatic cancer cells
Wang, H., Hang, C., Ou, X., Nie, J., Ding, Y.-T., Xue, S.-G., Gao, H., & Zhu, J. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0331-4 · Cited by 48
Kondo, A., Nonaka, A., Shimamura, T., Yamamoto, S., Yoshida, T., Kodama, T., Aburatani, H., & Osawa, T. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00125-17 · Cited by 44
“Angiogenesis plays an essential role in tumor growth and metastasis (6, 7).”
BackgroundBullard, J. D., Lei, J. L., Lim, J. J., Massee, M., Fallon, A. M., & Koob, T. J. (2018) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.34196 · Cited by 44
“It is known that VEGF and bFGF play an integral role in the stimulation, differentiation and establishment of angiogeneic networks by endothelial cells.(51) The effect from dHUC treatment is further validated by the presence of those angiogenic factors, as well as others such as angiogenin-4 and angiopoietin, in the t…”
BackgroundProlyl isomerase Pin1 in metabolic reprogramming of cancer cells
Nakatsu, Y., Yamamotoya, T., Ueda, K., Ono, H., Inoue, M.-K., Matsunaga, Y., Kushiyama, A., Sakoda, H., Fujishiro, M., Matsubara, A., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.043 · Cited by 44
Sun, Y., Hu, H., Jing, X., Meng, Q., Yu, B., Cong, H., & Shen, Y. (2021) · Science China Materials · doi:10.1007/s40843-020-1627-4 · Cited by 43
Maffucci, T., Raimondi, C., Abu‐Hayyeh, S., Dominguez, V., Sala, G., Zachary, I. C., & Falasca, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008285 · Cited by 49
Mesri, M., Birse, C., Heidbrink, J. L., McKinnon, K., Brand, E., Bermingham, C. L., Feild, B. J., FitzHugh, W., He, T., Ruben, S. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078885 · Cited by 42
Favaro, E., Nardo, G., Persano, L., Masiero, M., Moserle, L., Zamarchi, R., Rossi, E. M. C., Esposito, G., Plebani, M., Sattler, U. G. A., et al. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.071183 · Cited by 48
Mahal, K., Resch, M., Ficner, R., Schobert, R., Biersack, B., & Mueller, T. (2014) · ChemMedChem · doi:10.1002/cmdc.201300531 · Cited by 44
Lysyl oxidase in colorectal cancer
Cox, T. R., & Erler, J. T. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00425.2012 · Cited by 47
Ponticelli, S., Marasco, D., Tarallo, V., Albuquerque, R., Mitola, S. M. F., Takeda, A., Stassen, J.-M., Presta, M., Ambati, J., Ruvo, M., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806607200 · Cited by 42
Chitoran, E., Rotaru, V., Stefan, D. C., Gullo, G., & Simion, L. (2025) · Cancers · doi:10.3390/cancers17071126 · Cited by 45
Nielsen, T., Wittenborn, T. R., & Horsman, M. R. (2012) · Pharmaceutics · doi:10.3390/pharmaceutics4040563 · Cited by 41
“The AIs that target VEGF include monoclonal antibodies and inhibitors of endothelial cell receptor-associated tyrosine kinase activity [13–16].”
BackgroundMurakami, M., Zhao, S., Zhao, Y., CHOWDHURY, N. F., Yu, W., Nishijima, K., Takiguchi, M., Tamaki, N., & Kuge, Y. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1624 · Cited by 48
“Angiogenesis plays a critical role in tumor progression, invasion and metastasis (1,2).”
BackgroundFangusaro, J., Gururangan, S., Poussaint, T. Y., McLendon, R. E., Onar‐Thomas, A., Warren, K. E., Wu, S., Packer, R. J., Banerjee, A., Gilbertson, R. J., et al. (2013) · Cancer · doi:10.1002/cncr.28343 · Cited by 42
“Thrombocytopenia 24 (11) 4 (3) 0 (0) 0 (0) 28 13”
InfluentialEmerging treatment options for management of malignant ascites in patients with ovarian cancer
Tewari, K. S., & Eskander, R. N. (2012) · International Journal of Women s Health · doi:10.2147/ijwh.s29467 · Cited by 41
Sanchez-Pulido, L., & Ponting, C. P. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btv761 · Cited by 41
“Tight regulation of angiogenesis contributes to normal physiology, growth and development, but when misregulated leads to, or dramatically affects, pathological conditions, such as ischaemia, wound healing and cancer (Ferrara and Kerbel, 2005).”
Maurea, N., Spallarossa, P., Dessalvi, C. C., Madonna, R., Mele, D., Monte, I. P., Novo, G., Pagliaro, P., Pepe, A., Tocchetti, C. G., et al. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000383 · Cited by 41
Hassan, L. E. A., Dahham, S. S., Saghir, S. A. M., Mohammed, A. M. A., Eltayeb, N. M., Majid, A. M. S. A., & Majid, A. S. A. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1369-5 · Cited by 42
Körfer, J., Lordick, F., & Hacker, U. T. (2021) · Cancers · doi:10.3390/cancers13205216 · Cited by 46
Emerging Functions and Clinical Applications of Exosomal ncRNAs in Ovarian Cancer
Zhang, Y., Wei, Y.-J., Zhang, Y., Liu, H.-W., & Zhang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.765458 · Cited by 42
Gene therapy progress and prospects: therapeutic angiogenesis for ischemic cardiovascular disease
Vincent, K. A., Jiang, C., Boltje, I., & Kelly, R. A. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302953 · Cited by 42
Plantamura, I., Casalini, P., Dugnani, E., Sasso, M., D’Ippolito, E., Tortoreto, M., Cacciatore, M., Guarnotta, C., Ghirelli, C., Barajon, I., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.015 · Cited by 41
“Therefore, to evaluate whether themain pathways physiologically implicated in vessel formation by endothelial cells (i.e. VEGFR, PDFGR and/or FGFR) (Ferrara and Kerbel, 2005) could be responsible for this phenomenon, we used two different compounds, an antibody targeting VEGF (Bevacizumab) and a…”
MethodJia, Y., Liu, M., Huang, W., Wang, Z., He, Y., Wu, J., Ren, S., Ju, Y., Geng, R., & Li, Z. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9447-y · Cited by 42
“Furthermore, anti-VEGF-A monotherapy might even help tumors to switch on other angiogenic pathways for angiogenesis [28].”
BackgroundChen, L., Wu, M., & Dong, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031708 · Cited by 44
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway
Korpanty, G. J., Smyth, E. C., Sullivan, L. A., Brekken, R. A., & Carney, D. N. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2009.009191 · Cited by 47
The Role of FoxC2 Transcription Factor in Tumor Angiogenesis
Kume, T. (2011) · Journal of Oncology · doi:10.1155/2012/204593 · Cited by 45
“Hindawi Publishing Corporation Journal of Oncology Volume 2012, Article ID 204593, 7 pages doi:10.1155/2012/204593 Review Article The Role of FoxC2 Transcription Factor in Tumor Angiogenesis Tsutomu Kume Feinberg Cardiovascular Research Institute, Feinberg School of Medicine, Northwestern University, 303E Chicago Aven…”
InfluentialKim, E. H., & Surh, Y. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.07.043 · Cited by 42
Angiogenesis inhibitors in the treatment of prostate cancer
Kluetz, P. G., Figg, W. D., & Dahut, W. L. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903451716 · Cited by 47
“Both basic and clinical studies have shown that inhibition of angiogenesis can inhibit tumor progression and metastases [26].”
BackgroundKlement, H., Croix, B. S., Milsom, C., May, L. L., Guo, Q., Yu, J., Klement, P., & Rak, J. W. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070298 · Cited by 41
“The status of the vasculature could be of even greater importance for the efficacy of antiangiogenic therapies, the increasing role of which is epitomized by the recent approval of bevacizumab and at least two other agents.(15) It is noteworthy that the development of these new agents has been possible because of the…”
Buckel, L., Advani, S. J., Frentzen, A., Zhang, Q., Yu, Y., Chen, N. G., Ehrig, K., Stritzker, J., Mundt, A. J., & Szalay, A. A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28296 · Cited by 41
“Vascular endothelial growth factor (VEGF) is a key regulator of tumor angiogenesis and its pathway has been pharmacologically targeted with small molecules and antibodies.(21) Bevacizumab is an anti-VEGF antibody that has been clinically approved for recurrent GBM.”
BackgroundEstrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial
Chlebowski, R. T., Wakelee, H. A., Pettinger, M. B., Rohan, T. E., Liu, J., Simon, M. S., Tindle, H. A., Messina, C. R., Johnson, K., Schwartz, A. G., et al. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.09.004 · Cited by 41
Qi, X., Okamoto, Y., Murakawa, T., Wang, F., Oyama, O., Ohkawa, R., Yoshioka, K., Du, W., Sugimoto, N., Yatomi, Y., et al. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.02.038 · Cited by 40
“Therapeutic angiogenesis is an attractive strategy for treating patients with ischemia (Ferrara and Kerbel, 2005; Losordo and Dimmeler, 2004a).”
BackgroundMethodResultInfluentialGautier, B., Miteva, M. A., Gonçalves, V., Huguenot, F., Coric, P., Bouaziz, S., Seijo, B., Gaucher, J., Broutin, I., Garbay, C., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.10.016 · Cited by 47
Angiogenesis and parasitic helminth-associated neovascularization
Dennis, R. D., Schubert, U., & Bauer, C. (2011) · Parasitology · doi:10.1017/s0031182010001642 · Cited by 44
“…NO-dependent killing of schistosomula (Oswald et al. 1994a,b), migration and attachment during the active extravasation of eggs (Ngaiza et al. 1993; File, 1995), upregulation of the cell-adhesion molecules, intercellular adhesion molecule (ICAM)-1, E-selectin and vascular cell adhesion molecule…”
BackgroundRole of Endogenous Angiogenesis Inhibitors in Down Syndrome
Ryeom, S. W., & Folkman, J. (2009) · Journal of Craniofacial Surgery · doi:10.1097/scs.0b013e3181927f47 · Cited by 40
Antitumor activity of antimicrobial peptides against U937 histiocytic cell line.
Koszałka, P., Kamysz, E., Wejda, M., Kamysz, W., & Bigda, J. (2011) · Acta Biochimica Polonica · doi:10.18388/abp.2011_2293 · Cited by 44
Xu, Z., Fang, S., Zuo, Y., Zhang, Y., Cheng, R., Wang, Q., Yang, Z., Cai, W., Ma, J., Yang, X., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02013.x · Cited by 40
Sj, K., Lee, Y., Kim, N. Y., Hwang, Y., Hwang, B. Y., Min, J.-K., & Koh, S. S. (2012) · Oncogene · doi:10.1038/onc.2012.366 · Cited by 40
Liver cancer: Targeted future options
Pircher, A., Medinger, M., & Drevs, J. (2011) · World Journal of Hepatology · doi:10.4254/wjh.v3.i2.38 · Cited by 43
Cerezo, A. B., Winterbone, M. S., Moyle, C. W. A., Needs, P. W., & Kroon, P. A. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500407 · Cited by 44
“Vascular endothelial growth factor (VEGF) has been shown to be the most important pro-angiogenic growth factor in humans [9–11] exerting its angiogenic effects by stimulating VEGF receptor 2 (VEGFR-2), which is critical for promoting proliferation and differentiation of endothelial cells [11,12].”
BackgroundNaruse, T., Kawasaki, G., Yanamoto, S., Mizuno, A., & Umeda, M. (2011) · PubMed · Cited by 40
Targeting angiogenesis in endometrial cancer - new agents for tailored treatments
Papa, A., Zaccarelli, E., Caruso, D., Vici, P., Panici, P. B., & Tomao, F. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1116517 · Cited by 42
“In 1971 Folkman speculated that atypical angiogenesis could play a role for tumor growth and development of metastatic process [9,10] and therefore angiogenesis has been extensively investigated as a promising target for anti-cancer therapy in many solid tumors [11] (Figure 1, [11]).”
BackgroundMethodWang, H., Zhang, C., Chi, H., & Meng, Z. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4351 · Cited by 40
Petrović, J. D., Glamočlija, J., Tomic, T. I., Sokóvić, M., Robajac, D., Nedić, O., & Pavić, A. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.01.033 · Cited by 42
Tang, R., Xi, Y., Chai, W., Wang, Y., Guan, Y., Yang, G., Xie, H., & Chen, K. (2011) · Physics in Medicine and Biology · doi:10.1088/0031-9155/56/12/004 · Cited by 40
Angiogenesis and acute myeloid leukemia
Haouas, H. (2013) · Hematology · doi:10.1179/1607845413y.0000000139 · Cited by 44
Kawasaki, Y., Tsuji, S., Muroya, K., Furukawa, S., Shibata, Y., Okuno, M., Ohwada, S., & Akiyama, T. (2009) · EMBO Reports · doi:10.1038/embor.2009.233 · Cited by 50
“&2009 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION EMBO reports VOL 10 | NO 12 | 2009 scientificreport 1359 Crucial functions of Asefs in tumour angiogenesis Angiogenesis is a crucial process in the development of adenomas in ApcMin/þ mice, as well as in various human tumours (Ferrara & Kerbel, 2005).”
Bian, S., Zheng, X., Liu, W., Gao, Z., Wan, Y., Li, J., Ren, H., Zhang, W., Lee, C., & Wang, P. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122380 · Cited by 39
Decreased cell adhesion promotes angiogenesis in a Pyk2-dependent manner
Shen, C. J., Raghavan, S., Xu, Z., Baranski, J. D., Yu, X., Wozniak, M. A., Miller, J. S., Gupta, M., Buckbinder, L., & Chen, C. S. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.05.006 · Cited by 40
“Previous studies have demonstrated enhanced endothelial cell proliferation with increased cell spreading and ECM density [12,15], and inhibition of either endothelial proliferation or cell– ECM adhesion are proven mainstay strategies for developing antiangiogenic therapies [8,52].”
Lee, E. J., Park, H., Jeon, H.-J., Kim, H.-S., & Chang, M. (2013) · Regenerative Medicine · doi:10.2217/rme.13.17 · Cited by 44
Albendazole-cyclodextrin complex: enhanced cytotoxicity in ovarian cancer cells.
Pourgholami, M. H., Wangoo, K., & Morris, D. L. (2008) · PubMed · Cited by 43
Sánchez‐Martín, D., Martinez-Torrecuadrada, J. L., Teesalu, T., Sugahara, K. N., Álvarez‐Cienfuegos, A., Ximénez‐Embún, P., Fernández-Periañez, R., Martín, M. T., Molina-Privado, I., Ruppen, I., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300013110 · Cited by 40
An in vitro retinoblastoma human triple culture model of angiogenesis: A modulatory effect of TGF-β
Lupo, G., Motta, C., Salmeri, M., Spina-Purrello, V., Alberghina, M., & Anfuso, C. D. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.004 · Cited by 40
“treatments targeting VEGF or VEGFR-2 are currently used in advanced clinical trials for the therapy of several malignancies [19].”
MethodWang, J.-L., Liu, Y., Li, Y., Dai, W., Guo, Z., Wang, Z., & Zhang, Q. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9955 · Cited by 42
“(Invest Ophthalmol Vis Sci. 2012; 53:7348–7357) DOI:10.1167/iovs.12-9955 Choroidal neovascularization (CNV) causes severe visionloss, especially in AMD patients.1 Recently, different kinds of antiangiogenic agents have been used in the clinic to treat CNV.2,3 However, in order to maintain the therapeutic level of a dr…”
BackgroundInfluentialKim, D., Dai, J., Park, Y.-H., Yenwongfai, L. N., Wang, L., Pratheeshkumar, P., Son, Y., Kondo, K., Xu, M., Luo, J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.715797 · Cited by 42
RetractedRazavi, M., Hu, S., & Thakor, A. S. (2018) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36428 · Cited by 40
Lu, T., Wu, B., Yu, Y., Zhu, W., Zhang, S., Zhang, Y., Guo, J., & Deng, N. (2018) · Cancer Science · doi:10.1111/cas.13633 · Cited by 39
“Research on tumor angiogenesis had progressed slowly until important discoveries of the major molecular drivers of tumor angiogenesis: the VEGF family and its homologous receptors.(12) In addition to VEGF, other important pathways also contribute to tumor angiogenesis.”
BackgroundRetractedTherapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers
Karim, M. E., Tha, K. K., Othman, I., Uddin, M. B., & Chowdhury, E. H. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020065 · Cited by 40
Rangger, Helbok, von Guggenberg, E., Radolf, Prassl, R., Andreae, Thurner, Haubner, Decristoforo, C., & Sosabowski (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s36847 · Cited by 40
Development of anticancer drugs based on the hallmarks of tumor cells
Bailón-Moscoso, N., Romero-Benavides, J. C., & Ostrosky‐Wegman, P. (2014) · Tumor Biology · doi:10.1007/s13277-014-1649-y · Cited by 52
Yi, E.-Y., & Kim, Y.-J. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1616 · Cited by 44
“In addition, tumors produce a wide array of angiogenic molecules during angiogenesis (4).”
BackgroundZhang, X., Raghavan, S., Ihnat, M. A., Hamel, E., Zammiello, C. L., Bastian, A., Mooberry, S. L., & Gangjee, A. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.061 · Cited by 44
An Imageable Metastatic Treatment Model of Nasopharyngeal Carcinoma
Liu, T., Ding, Y., Xie, W., Li, Z., Bai, X., Li, X., Fang, W., Ren, C., Wang, S., Hoffman, R. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0089 · Cited by 39
Metadata
- Authors
- Ferrara, N., & Kerbel, R. S.
- Affiliations
- Genentech (US)
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature
- Published
- 2005-12
- Volume
- 438
- Issue
- 7070
- Pages
- 967-974
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2084740377
- Semantic Scholar
- 19591ab68a155b2d341266c48a9ef957bd4ba612
- Cited by
- 2,653
- References
- 102
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 72 · 2023: 69 · 2022: 75 · 2021: 102 · 2020: 114 · 2019: 95 · 2018: 97 · 2017: 124 · 2016: 160 · 2015: 164 · 2014: 158 · 2013: 171 · 2012: 164
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- angiogenesis, anti-angiogenic therapy, therapeutic angiogenesis, cancer therapy, age-related macular degeneration, antiangiogenic drugs, vascular morphogenesis
- MeSH terms
- Animals, Bone Marrow Cells, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.